WO2022220610A1 - 스핑고신-1-인산 수용체 효능제 합성을 위한 중간체의 제조방법 - Google Patents
스핑고신-1-인산 수용체 효능제 합성을 위한 중간체의 제조방법 Download PDFInfo
- Publication number
- WO2022220610A1 WO2022220610A1 PCT/KR2022/005398 KR2022005398W WO2022220610A1 WO 2022220610 A1 WO2022220610 A1 WO 2022220610A1 KR 2022005398 W KR2022005398 W KR 2022005398W WO 2022220610 A1 WO2022220610 A1 WO 2022220610A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- compound
- reaction
- chloro
- crystallization
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 30
- 230000015572 biosynthetic process Effects 0.000 title abstract description 26
- 238000003786 synthesis reaction Methods 0.000 title abstract description 26
- 229940121846 Sphingosine 1-phosphate receptor agonist Drugs 0.000 title abstract description 5
- 150000001875 compounds Chemical class 0.000 claims abstract description 120
- 238000004519 manufacturing process Methods 0.000 claims abstract description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 50
- 238000002425 crystallisation Methods 0.000 claims description 46
- 230000008025 crystallization Effects 0.000 claims description 46
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 42
- 125000000217 alkyl group Chemical group 0.000 claims description 24
- 239000002904 solvent Substances 0.000 claims description 23
- 125000003158 alcohol group Chemical group 0.000 claims description 21
- 229910052736 halogen Inorganic materials 0.000 claims description 17
- 229910052739 hydrogen Inorganic materials 0.000 claims description 17
- 239000001257 hydrogen Substances 0.000 claims description 17
- 150000002367 halogens Chemical class 0.000 claims description 16
- 229910052757 nitrogen Inorganic materials 0.000 claims description 11
- 150000002431 hydrogen Chemical group 0.000 claims description 10
- 230000000903 blocking effect Effects 0.000 claims description 8
- 238000005859 coupling reaction Methods 0.000 claims description 8
- 239000012046 mixed solvent Substances 0.000 claims description 8
- 239000000460 chlorine Substances 0.000 claims description 7
- 239000005456 alcohol based solvent Substances 0.000 claims description 6
- 125000006241 alcohol protecting group Chemical group 0.000 claims description 6
- 229910052799 carbon Inorganic materials 0.000 claims description 6
- 230000002378 acidificating effect Effects 0.000 claims description 5
- 239000007795 chemical reaction product Substances 0.000 claims description 5
- 238000006900 dealkylation reaction Methods 0.000 claims description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- 229910052794 bromium Inorganic materials 0.000 claims description 4
- 229910052801 chlorine Inorganic materials 0.000 claims description 4
- 229910052740 iodine Inorganic materials 0.000 claims description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- 125000001424 substituent group Chemical group 0.000 claims description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 2
- 239000011630 iodine Substances 0.000 claims description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 2
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 claims description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
- 239000011574 phosphorus Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 abstract description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Substances OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 73
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 71
- 238000006243 chemical reaction Methods 0.000 description 66
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 48
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 37
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 36
- QOFFFCUMPDREKF-UHFFFAOYSA-N 1-chloro-6-hydroxy-3,4-dihydronaphthalene-2-carbaldehyde Chemical compound ClC1=C(C=O)CCC2=CC(O)=CC=C21 QOFFFCUMPDREKF-UHFFFAOYSA-N 0.000 description 28
- WNJWMBXSURBCBT-UHFFFAOYSA-N 1-chloro-6-[(3-chloro-1-propan-2-ylindazol-5-yl)methoxy]-3,4-dihydronaphthalene-2-carbaldehyde Chemical compound ClC1=C(C=O)CCC2=CC(OCC=3C=C4C(Cl)=NN(C4=CC=3)C(C)C)=CC=C21 WNJWMBXSURBCBT-UHFFFAOYSA-N 0.000 description 15
- 150000001299 aldehydes Chemical class 0.000 description 15
- 235000019439 ethyl acetate Nutrition 0.000 description 15
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 14
- 102000011011 Sphingosine 1-phosphate receptors Human genes 0.000 description 14
- 108050001083 Sphingosine 1-phosphate receptors Proteins 0.000 description 14
- 238000004128 high performance liquid chromatography Methods 0.000 description 14
- 238000004190 ion pair chromatography Methods 0.000 description 14
- 239000010410 layer Substances 0.000 description 14
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 13
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 13
- 239000011248 coating agent Substances 0.000 description 13
- 238000000576 coating method Methods 0.000 description 13
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 12
- KCMGDIFNSMTREF-UHFFFAOYSA-N 6-hydroxy-3,4-dihydro-2H-naphthalen-1-one Chemical compound O=C1CCCC2=CC(O)=CC=C21.O=C1CCCC2=CC(O)=CC=C21 KCMGDIFNSMTREF-UHFFFAOYSA-N 0.000 description 10
- 238000003756 stirring Methods 0.000 description 10
- 239000000543 intermediate Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- DUYSYHSSBDVJSM-KRWOKUGFSA-N sphingosine 1-phosphate Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)COP(O)(O)=O DUYSYHSSBDVJSM-KRWOKUGFSA-N 0.000 description 9
- 238000001308 synthesis method Methods 0.000 description 9
- XXWLKFLYCRSTFP-UHFFFAOYSA-N (3-chloro-1-propan-2-ylindazol-5-yl)methanol Chemical compound OCC1=CC=C2N(C(C)C)N=C(Cl)C2=C1 XXWLKFLYCRSTFP-UHFFFAOYSA-N 0.000 description 8
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- 239000012044 organic layer Substances 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 239000011541 reaction mixture Substances 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- -1 3-chloro-1-isopropyl-1H-indazol-5-ylmethoxy Chemical group 0.000 description 7
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 7
- 230000002776 aggregation Effects 0.000 description 7
- 239000002585 base Substances 0.000 description 7
- 239000002981 blocking agent Substances 0.000 description 7
- 239000007810 chemical reaction solvent Substances 0.000 description 7
- 210000004698 lymphocyte Anatomy 0.000 description 7
- XTRBBCJVBLRZPE-UHFFFAOYSA-N methyl 3-chloro-1-propan-2-ylindazole-5-carboxylate Chemical compound COC(=O)C1=CC=C2N(C(C)C)N=C(Cl)C2=C1 XTRBBCJVBLRZPE-UHFFFAOYSA-N 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 7
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 7
- 238000005406 washing Methods 0.000 description 7
- PGBLWZHEVPQHHW-UHFFFAOYSA-N CC(OC(C=C1)=CC(CC2)=C1C(Cl)=C2C=O)=O Chemical compound CC(OC(C=C1)=CC(CC2)=C1C(Cl)=C2C=O)=O PGBLWZHEVPQHHW-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- 238000001035 drying Methods 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 235000015320 potassium carbonate Nutrition 0.000 description 6
- 229910000027 potassium carbonate Inorganic materials 0.000 description 6
- 229940044601 receptor agonist Drugs 0.000 description 6
- 239000000018 receptor agonist Substances 0.000 description 6
- 238000011084 recovery Methods 0.000 description 6
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 5
- 239000012346 acetyl chloride Substances 0.000 description 5
- 239000013078 crystal Substances 0.000 description 5
- 238000004821 distillation Methods 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 201000006417 multiple sclerosis Diseases 0.000 description 5
- WAOFGBYYAVBKDW-UHFFFAOYSA-N 6-methoxy-3,4-dihydro-2H-naphthalen-1-one Chemical compound O=C1CCCC2=CC(OC)=CC=C21.O=C1CCCC2=CC(OC)=CC=C21 WAOFGBYYAVBKDW-UHFFFAOYSA-N 0.000 description 4
- GNZJLIGRTVGHMF-UHFFFAOYSA-N CC(C)N(C1=CC=C(CBr)C=C11)N=C1Cl Chemical compound CC(C)N(C1=CC=C(CBr)C=C11)N=C1Cl GNZJLIGRTVGHMF-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 102100025750 Sphingosine 1-phosphate receptor 1 Human genes 0.000 description 4
- 101710155454 Sphingosine 1-phosphate receptor 1 Proteins 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 238000005054 agglomeration Methods 0.000 description 4
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- FMKOJHQHASLBPH-UHFFFAOYSA-N isopropyl iodide Chemical compound CC(C)I FMKOJHQHASLBPH-UHFFFAOYSA-N 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- BDKNTMQPRHCITN-UHFFFAOYSA-N 1-chloro-6-methoxy-3,4-dihydronaphthalene-2-carbaldehyde Chemical compound ClC1=C(C=O)CCC2=CC(OC)=CC=C21 BDKNTMQPRHCITN-UHFFFAOYSA-N 0.000 description 3
- FIQRFGMXMPFPRK-UHFFFAOYSA-N CC(C)N(C1=CC(COC(C=C2CC3)=CC=C2C(Cl)=C3C=O)=CC=C11)N=C1Cl Chemical compound CC(C)N(C1=CC(COC(C=C2CC3)=CC=C2C(Cl)=C3C=O)=CC=C11)N=C1Cl FIQRFGMXMPFPRK-UHFFFAOYSA-N 0.000 description 3
- FYBHCMAHQKJAFA-UHFFFAOYSA-N CC(C)N(C1=CC=C(COC(C=C2CCC3)=CC=C2C3=O)C=C11)N=C1Cl Chemical compound CC(C)N(C1=CC=C(COC(C=C2CCC3)=CC=C2C3=O)C=C11)N=C1Cl FYBHCMAHQKJAFA-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 239000012267 brine Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 3
- 210000003563 lymphoid tissue Anatomy 0.000 description 3
- LPLOEZPPYOSNEW-UHFFFAOYSA-N methyl 1h-indazole-5-carboxylate Chemical compound COC(=O)C1=CC=C2NN=CC2=C1 LPLOEZPPYOSNEW-UHFFFAOYSA-N 0.000 description 3
- GGULXYLLYYPWQZ-UHFFFAOYSA-N methyl 3-chloro-2h-indazole-5-carboxylate Chemical compound C1=C(C(=O)OC)C=CC2=NNC(Cl)=C21 GGULXYLLYYPWQZ-UHFFFAOYSA-N 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- 125000000547 substituted alkyl group Chemical group 0.000 description 3
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 2
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 2
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 238000005874 Vilsmeier-Haack formylation reaction Methods 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 125000003172 aldehyde group Chemical group 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 230000008209 cardiovascular development Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 229940106189 ceramide Drugs 0.000 description 2
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 2
- DQYBDCGIPTYXML-UHFFFAOYSA-N ethoxyethane;hydrate Chemical compound O.CCOCC DQYBDCGIPTYXML-UHFFFAOYSA-N 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hcl hcl Chemical compound Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 2
- 239000012280 lithium aluminium hydride Substances 0.000 description 2
- GUVLZYAZFWASMH-UHFFFAOYSA-N methyl 1-propan-2-ylindazole-5-carboxylate Chemical compound COC(=O)C1=CC=C2N(C(C)C)N=CC2=C1 GUVLZYAZFWASMH-UHFFFAOYSA-N 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- OQJBFFCUFALWQL-UHFFFAOYSA-N n-(piperidine-1-carbonylimino)piperidine-1-carboxamide Chemical compound C1CCCCN1C(=O)N=NC(=O)N1CCCCC1 OQJBFFCUFALWQL-UHFFFAOYSA-N 0.000 description 2
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 108010035597 sphingosine kinase Proteins 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- ZZMYWYZPNZRYPX-SANMLTNESA-N (2r)-2-amino-2-[5-[4-[2-(4-phenylphenyl)ethoxy]-3-(trifluoromethyl)phenyl]-1h-imidazol-2-yl]propan-1-ol Chemical compound N1C([C@@](N)(CO)C)=NC=C1C(C=C1C(F)(F)F)=CC=C1OCCC1=CC=C(C=2C=CC=CC=2)C=C1 ZZMYWYZPNZRYPX-SANMLTNESA-N 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
- BXVSAYBZSGIURM-UHFFFAOYSA-N 2-phenoxy-4h-1,3,2$l^{5}-benzodioxaphosphinine 2-oxide Chemical compound O1CC2=CC=CC=C2OP1(=O)OC1=CC=CC=C1 BXVSAYBZSGIURM-UHFFFAOYSA-N 0.000 description 1
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 1
- MNALUTYMBUBKNX-UHFFFAOYSA-N 6-methoxy-3,4-dihydro-2h-naphthalen-1-one Chemical compound O=C1CCCC2=CC(OC)=CC=C21 MNALUTYMBUBKNX-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- RHBRHRRVFZHTTC-UHFFFAOYSA-N CC(C)N(C1=CC=C(COC2=CC=C(C=C(CC3)C=O)C3=C2)C=C11)N=C1Cl Chemical compound CC(C)N(C1=CC=C(COC2=CC=C(C=C(CC3)C=O)C3=C2)C=C11)N=C1Cl RHBRHRRVFZHTTC-UHFFFAOYSA-N 0.000 description 1
- 101000703517 Dictyostelium discoideum Sphingosine-1-phosphate lyase Proteins 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 102100029802 Sphingosine 1-phosphate receptor 5 Human genes 0.000 description 1
- 101710155451 Sphingosine 1-phosphate receptor 5 Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108010002321 Tight Junction Proteins Proteins 0.000 description 1
- 102000000591 Tight Junction Proteins Human genes 0.000 description 1
- JFBZPFYRPYOZCQ-UHFFFAOYSA-N [Li].[Al] Chemical compound [Li].[Al] JFBZPFYRPYOZCQ-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 230000019552 anatomical structure morphogenesis Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 230000003436 cytoskeletal effect Effects 0.000 description 1
- 230000020335 dealkylation Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000008753 endothelial function Effects 0.000 description 1
- KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 description 1
- 229960000556 fingolimod Drugs 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 231100001261 hazardous Toxicity 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 230000006749 inflammatory damage Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- SRJOCJYGOFTFLH-UHFFFAOYSA-N isonipecotic acid Chemical compound OC(=O)C1CCNCC1 SRJOCJYGOFTFLH-UHFFFAOYSA-N 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- PVWOIHVRPOBWPI-UHFFFAOYSA-N n-propyl iodide Chemical compound CCCI PVWOIHVRPOBWPI-UHFFFAOYSA-N 0.000 description 1
- 210000003061 neural cell Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000012958 reprocessing Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 108010066791 sphingosine-1-phosphate phosphatase Proteins 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001578 tight junction Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- TUQOTMZNTHZOKS-UHFFFAOYSA-N tributylphosphine Chemical compound CCCCP(CCCC)CCCC TUQOTMZNTHZOKS-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/004—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reaction with organometalhalides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
- C07C45/64—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by introduction of functional groups containing oxygen only in singly bound form
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
- C07C45/65—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by splitting-off hydrogen atoms or functional groups; by hydrogenolysis of functional groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/78—Separation; Purification; Stabilisation; Use of additives
- C07C45/81—Separation; Purification; Stabilisation; Use of additives by change in the physical state, e.g. crystallisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C47/00—Compounds having —CHO groups
- C07C47/02—Saturated compounds having —CHO groups bound to acyclic carbon atoms or to hydrogen
- C07C47/19—Saturated compounds having —CHO groups bound to acyclic carbon atoms or to hydrogen containing hydroxy groups
- C07C47/192—Saturated compounds having —CHO groups bound to acyclic carbon atoms or to hydrogen containing hydroxy groups containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C47/00—Compounds having —CHO groups
- C07C47/02—Saturated compounds having —CHO groups bound to acyclic carbon atoms or to hydrogen
- C07C47/19—Saturated compounds having —CHO groups bound to acyclic carbon atoms or to hydrogen containing hydroxy groups
- C07C47/195—Saturated compounds having —CHO groups bound to acyclic carbon atoms or to hydrogen containing hydroxy groups containing halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C67/00—Preparation of carboxylic acid esters
- C07C67/14—Preparation of carboxylic acid esters from carboxylic acid halides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Definitions
- the present invention relates to a process for the preparation of key intermediates for the synthesis of sphingosine-1-phosphate receptor agonists.
- Sphingosine-1-phosphate is produced through the intracellular ceramide pathway, and ceramide, the starting material of this synthetic pathway, has two production pathways, namely, the de novo biosynthetic pathway and It is produced in cells through the degradation of sphingomyelin, a component of the cell membrane.
- S1P levels in each tissue are regulated by two biosynthetic sphingosine kinases (SphKs) and two biodegradable S1P phosphatases (S1P lyase and lysophospholipid phosphatases).
- S1P lyase and lysophospholipid phosphatases The produced substance S1P mediates various cellular responses such as cell proliferation, cytoskeletal organization and migration, adhesion- and tight junction assembly, and morphogenesis. it is known They are present in high concentrations (100-1000 nM) in plasma bound to albumin and other plasma proteins, whereas in tissues, they are present in low concentrations.
- S1P binds to the S1P receptor, a G-protein coupled receptor, and exhibits various biological functions.
- the sub-types of S1P receptors known to date are S1P1 to S1P5. ) receptor) 1, 5, 3, 6 and 8. These S1P receptors are responsible for leukocyte recirculation, neural cell proliferation, morphological changes, migration, endothelial function, vasoregulation and cardiovascular development ( It is known to be involved in various biological functions such as cardiovascular development.
- S1P signaling through these receptors plays an important role in a series of responses related to multiple sclerosis, including inflammatory responses and repair processes.
- nonselective S1P1 agonists have recently It is approved for the treatment of multiple sclerosis.
- S1P receptors are equally widely expressed in many cells involved in the induction of multiple sclerosis.
- S1P1 receptors play a very important role in the immune system.
- the S1P1 receptor is mainly expressed on the surface of lymphocytes such as T cells and B cells, and reacts with S1P to participate in lymphocyte recycling.
- the S1P concentration is higher in body fluid than in lymphoid tissue, so that lymphocytes leave the lymphoid tissue according to the difference in S1P concentration and circulate along the efferent lymph.
- the S1P1 receptor of lymphocytes is down-regulated by the S1P1 agonist, the egress of lymphocytes from the lymphoid tissue does not occur, and eventually autoaggressive causing inflammation and tissue damage to the CNS. The infiltration of lymphocytes is reduced, and the therapeutic effect appears in multiple sclerosis.
- fingolimod a nonselective S1P1 agonist approved as an oral multiple sclerosis treatment, when it is activated by binding to the S1P1 receptor, paradoxically, the receptor is internalized or degraded from the lymphocyte surface, resulting in functional S1P1 It acts as an antagonist.
- Korean Patent Application Laid-Open No. 10-2014-0104376 discloses a novel compound of Formula 1 effective as an S1P receptor agonist.
- X is C or N
- R1 is H or optionally substituted alkyl
- R2 is H, optionally substituted alkyl, halogen, CN, CF 3 or COCF 3 ,
- W is C, N, C-alkoxy, C-halogen or C-CN
- n 0, 1, 2 or 3
- R3 to R10 are each H, alkyl, halogen, halogenoalkyl or alkoxyalkyl,
- R11 is H
- R12 is OH, NH 2 , or to be.
- reaction may have the following problems in producing a clinical API.
- the filtered solid was washed sequentially with water and MTBE, respectively, and then dried over nitrogen to 6-(3-chloro-1-isopropyl-1H-indazol-5-ylmethoxy)-3,4-dihydro-2H -Naphthalen-1-one was obtained.
- Phosphoryl chloride (POCl 3 ) was added to the reactor and the internal temperature was cooled to 0 °C. DMF was slowly added dropwise, and after stirring at an internal temperature of 50° C. for 2 hours, 6-(3-chloro-1-isopropyl-1H-indazol-5-ylmethoxy)-3,4-dihydro-2H-naphthalene -1-one was added and reacted at an internal temperature of 50° C. for 3 hours. Since excessive HCl gas was generated during the reaction, a vent line was installed so that it could be neutralized by installing a NaOH trap.
- an object of the present invention is to provide a suitable method for producing the compound of Formula 4, which is a key intermediate in a novel synthesis method of an excellent sphingosine-1-phosphate receptor agonist, in high yield.
- R1 is hydrogen or substituted or unsubstituted alkyl
- R2 is hydrogen, substituted or unsubstituted alkyl, halogen, CN, CF 3 or COCF 3 ;
- R3 and R4 are each hydrogen, substituted or unsubstituted alkyl, or halogen
- R5 is hydrogen, substituted or unsubstituted alkyl or halogen
- X is C or N
- L is a leaving group
- One aspect according to the present invention provides a method for preparing an intermediate compound of Formula 4, comprising preparing an intermediate compound of Formula 4 by a coupling reaction between a compound of Formula 2 and a compound of Formula 3.
- R1 is hydrogen or substituted or unsubstituted alkyl
- R2 is hydrogen, substituted or unsubstituted alkyl, halogen, CN, CF 3 or COCF 3 ;
- R3 and R4 are each hydrogen, substituted or unsubstituted alkyl, or halogen
- R5 is hydrogen, substituted or unsubstituted alkyl or halogen
- X is C or N
- L is a leaving group
- the 'alkyl' is a substituted alkyl
- substituents there may be one or more substituents, and the substituents are each independently a group consisting of halogen, cyano, hydroxy, alkyloxy, oxo, unsubstituted sulfonyl and sulfonyl substituted with alkyl. It may be selected from
- R1 of the above formula is hydrogen or C 1 -C 6 substituted or unsubstituted alkyl
- R2 is hydrogen, C 1 -C 6 substituted or unsubstituted alkyl, halogen, CN, It may be CF 3 or COCF 3
- Each of R3 and R4 may be hydrogen or C 1 -C 6 substituted or unsubstituted alkyl
- R5 may be F, Cl, Br or I.
- R1 may be C 1 -C 4 substituted or unsubstituted alkyl, and R2 may be halogen (F, Cl, Br or I).
- R3 and R4 may be hydrogen.
- R5 may be Cl.
- the leaving group (L) is a reactive group that provides a substitution position to the compound of Formula 2 when the compound of Formula 2 is subjected to a substitution reaction with an alcohol-based compound such as Formula 3, but is not limited thereto.
- it may be selected from chlorine (Cl), bromine (Br), iodine (I), methanesulfonate (Oms), p-toluenesulfonate (OTs) and trifluoromethanesulfonate (OTf). have.
- L may be Br.
- the compound of Formula 4 is prepared by a coupling reaction between the compound of Formula 2 and the compound of Formula 3.
- the coupling reaction of the compound of Formula 2 and the compound of Formula 3 can be easily performed using K 2 CO 3 in a dimethylformamide (DMF) solvent.
- DMF dimethylformamide
- the solvent for crystallization of the compound of Formula 4 includes an alcohol-based solvent. It may be preferable to use For example, when water or methyl tertiary butyl ether (MTBE) is used alone during crystallization of the compound of Formula 4, crystallization may not proceed.
- MTBE methyl tertiary butyl ether
- the 'alcohol solvent' for crystallization of the compound of Formula 4 is not limited thereto, but may be, for example, at least one solvent selected from methanol, ethanol, isopropyl alcohol, and butanol.
- the solvent for the crystallization may be a mixed solvent of an alcohol-based solvent and water.
- a mixed solvent of an alcohol-based solvent and water as the crystallization solvent, there may be an effect of crystallizing the compound of Formula 4 and obtaining the compound of Formula 4 in high yield.
- the volume ratio of the alcohol solvent and water in terms of the yield of Chemical Formula 4 is 5:1 to 1:5, 4:1 to 1:4, 3:1 to 1:3, 2:1 to 3:1, 1:1 to 3:1, 1:1 to 2.5:1 or 1:2.5 may be used.
- the solvent for the crystallization may be a mixed solvent of ethanol and water. Specifically, the volume ratio of ethanol and water to EtOH:H 2 O 5:1 to 1:5, 4:1 to 1:4, 3:1 to 1:3, 2:1 to 3:1, 1:1 to 3:1, 1:1 to 2.5:1 or 1:2.5 may be used.
- the compound of Formula 3 may be prepared from the compound of Formula 5.
- the compound of Formula 3 may be obtained by introducing an aldehyde into the compound of Formula 5.
- the reaction of introducing the aldehyde into the compound of Formula 5 may be performed using a reagent of the Vilsmeier-Haack reaction.
- reaction of introducing an aldehyde into the compound of Formula 5 is reacting the compound of Formula 5 with phosphoryl chloride (POCl 3 ) and dimethylformamide (DMF) to prepare a compound of Formula 3 may be doing
- the reaction of introducing the aldehyde into the compound of Formula 5 is performed at a temperature of 30° C. or less, thereby stabilizing the exothermic problem caused by the Vilsmeyer-nuclear reaction.
- reaction of introducing an aldehyde into the compound of Formula 5 may be performed at a temperature of 0°C to 25°C.
- reaction of introducing an aldehyde to the compound of Formula 5 may be prepared by the following steps.
- Y is an alcohol-protecting group.
- the aldehyde is introduced without blocking the alcohol group of the compound of Formula 5, and the compound of Formula 3 can be prepared by simplifying the process, but in terms of the yield of the compound of Formula 3, the alcohol group of the compound of Formula 5 is After blocking with an alcohol protecting group, the aldehyde introduction reaction may be performed.
- Blocking the alcohol group in the compound of Formula 5 may be performed according to a known alcohol blocking method, and the method is not particularly limited.
- the alcohol protecting group (Y) introduced into the compound of Formula 5 is not particularly limited as long as it is a known alcohol protecting group, for example, an acetyl group (-Ac), a trimethylsilyl group (-TMS), and a tert-butyldimethylsilyl group. group (-TBDMS), and the like, but is not limited thereto.
- a known alcohol protecting group for example, an acetyl group (-Ac), a trimethylsilyl group (-TMS), and a tert-butyldimethylsilyl group. group (-TBDMS), and the like, but is not limited thereto.
- the step of preparing the compound of Formula 7 by introducing the aldehyde into the compound of Formula 6 in which the alcohol is blocked may be performed according to the same method as the step of introducing the aldehyde into the compound of Formula 5 in which the alcohol group is not blocked.
- the alcohol group may be recovered using an alcohol deblocking agent suitable for the alcohol protecting group to prepare the compound of Formula 3.
- the alcohol de-blocking agent may use a known base material, for example, K 2 CO 3 , NaHCO 3 , and NaOH, and the like may be mentioned, but is not limited thereto.
- reaction solvent may be appropriately selected according to the type of the de-blocking agent used in the alcohol recovery reaction.
- the reaction solvent is an alcoholic solvent, for example, methanol, ethanol, or a mixture thereof. It may be a solvent.
- the compound of Formula 3 may be prepared.
- the compound of Formula 3 prepared as described above may be crystallized to obtain a compound of Formula 3 with high purity.
- the compound of Formula 3 is prepared through a series of steps without a purification process between each step, purity can be improved through crystallization.
- the crystallization of the compound of Formula 3 may be performed under acidic conditions.
- the acidic condition may be, for example, a condition of pH 4.0 or less, specifically, crystallization by adding an acid compound so that the pH of the solution containing the compound of Formula 3 is 3.0 to 4.0.
- the acid compound used for forming the acidic condition may be a known acid compound within a range that does not impair the structure and physical properties of the compound of Formula 3, and the type of the acid compound is not limited.
- hydrochloric acid may be added to the reaction product containing the compound of Formula 3 to perform crystallization.
- water (H 2 O) and hydrochloric acid (HCl) are simultaneously or sequentially added to the reaction product containing the compound of Formula 3 to perform crystallization.
- it may be carried out by adding hydrochloric acid after adding water to the reaction product containing the compound of Formula 3 above.
- the reaction solvent such as methanol
- crystallization of the compound of Formula 3 may be performed.
- crystallization of the compound of Formula 3 may be performed without distillation of a reaction solvent, such as methanol, after terminating the reaction for recovering the alcohol group.
- a reaction solvent such as methanol
- the crystallization of the compound of Formula 3 may be carried out at a reaction temperature of 10° C. or less.
- the reaction temperature during crystallization of the compound of Formula 3 is 10° C. or less, and the dropwise addition of hydrochloric acid is less than 2 hours, for example, 1 hour, 30 minutes, 20 minutes or 10 minutes. it could be
- the compound of Formula 5 may be prepared by a dealkylation reaction of the compound of Formula 8.
- R3 and R4 are as defined above, and R6 is substituted or unsubstituted alkyl.
- R6 may be an unsubstituted C 1 ⁇ C 4 alkyl.
- R6 may be a methyl group.
- the compound of Formula 3 may be prepared by introducing an aldehyde into the compound of Formula 8 according to the same method as for introducing an aldehyde into the compound of Formula 5 or Formula 6, but A problem in that the compound of Formula 8 is decomposed by performing a dealkylation reaction from the compound of Formula 8 to prepare a compound of Formula 5, and introducing an aldehyde into the compound of Formula 5 or 6 to prepare a compound of Formula 3 By improving the intermediate compound can be prepared in high yield even in mass production.
- the dealkylation reaction of the compound of Formula 8 may be carried out according to a known method capable of preparing the compound of Formula 5 by substituting an alcohol group for the alkyl group of R6, and the method and the type of reagent used are particularly limited. it is not
- the dealkylation of the compound of Formula 8 is selected from, for example, hydrogen bromide (HBr), aluminum chloride (AlCl 3 ), and iron (III) chloride (FeCl 3 ). may be used, but is not limited thereto.
- the compounds prepared according to the present invention can be used as key intermediates for the synthesis of sphingosine-1-phosphate receptor agonists.
- the compound prepared according to the present invention can be used as a main intermediate in a known synthesis method of a sphingosine-1-phosphate receptor agonist, and can also be used as a main intermediate in a new synthesis method developed after the present application.
- the use of the present invention is not limited to a particular method of synthesis of a sphingosine-1-phosphate receptor agonist.
- the compounds prepared according to the present invention can be used for other purposes other than the synthesis of sphingosine-1-phosphate receptor agonists, and the use of the present invention is limited only to the synthesis of sphingosine-1-phosphate receptor agonists. it is not
- the use of the preparation method of the present invention has the effect of mass-producing the compound of Formula 4 in high yield.
- Reaction ion pair chromatography was performed by HPLC, and the reaction was completed (1H-indazole-5-carboxylic acid methyl ester: N/D).
- the external temperature was set to 0° C., and cooling was performed for 60 minutes.
- K 2 CO 3 (10.7 kg, 77.4 mol)
- 2-iodopropane iodopropane, 8.98 kg, 52.8 mol
- B-complex (which is produced by NaBH 4 (3-chloro-1-isopropyl-1H-indazol-5-yl)-methanol alcohol and boron conjugated) and residual NaBH 4
- 3N HCl 39.3 kg was slowly added for 60 minutes to maintain the pH of the reaction solution at 3.0 and distilled under reduced pressure to remove the solvent.
- HBr HBr in H 2 O
- 6-methoxy-3,4-dihydro-2H-naphthalen-1-one (6-Methoxy-3,4-dihydro- 2H-naphthalen-1-one) (4.72 kg, 26.8 mol) was added and refluxed for 16.5 hours at an external temperature of 100°C.
- 6-hydroxy-3,4-dihydro-2H-naphthalen-1-one (4.22 kg, 26.0 mol) and DCM (20.2 L, 5 fold) were added to the reactor, and the internal temperature was cooled to 0°C.
- AcCl (2.14 kg, 27.3 mol) was added dropwise at 10 °C or lower for 15 minutes, and when the addition was completed, TEA (3.02 kg, 29.8 mol) was added dropwise at 10 °C or lower to proceed with the reaction.
- IPC was performed by HPLC, and the reaction was completed (5-oxo-5,6,7,8-tetrahydrotaphthalen-2-yl acetate: 0.4%) to terminate the reaction.
- Water (45.6 L, 10 fold) was added to another reactor and the internal temperature was cooled to 0 °C.
- the above reaction mixture was diluted with EtOAc (31.9 L, 7 fold) and slowly added dropwise so as not to exceed 25° C. to decompose the remaining POCl 3 to perform quenching.
- the organic layer was collected in another reactor, the aqueous layer was further extracted with EtOAc (13.7 L, 3 fold), the aqueous layer was removed, and the organic layer was added to the reactor containing the first layer separation organic layer.
- the collected organic layers were washed with water (22.8 L, 5 fold) and distilled under reduced pressure to synthesize the title compound (4.74 kg, Net yield 85.0%).
- Reaction IPC was carried out by HPLC, and the reaction was completed (1-chloro-6-hydroxy-3,4-dihydronaphthalene-2-carbaldehyde: 0.06%), and the internal temperature was cooled to 10 °C. A mixture of EtOH (13.1 L, 4 fold) and water (32.6 L, 10 fold) was slowly added to the reaction mixture to proceed with crystallization. When the input was completed, the internal temperature was cooled to 0 °C, aged for 1 hour, and the resulting solid was filtered. The filtered solid was washed with water (16.4 L) and n -Hexane (16.3 L) and dried over nitrogen. After drying, residual moisture was confirmed using a K/F device (water content: 0.20%). Finally, the title compound (6.36 kg, Net yield 89.7%) was synthesized.
- SG28 represents "5-chloro-6-formyl-7,8-dihydronaphthalen-2-yl acetate
- SG35 represents "1-chloro-6-hydroxy-3,4 -dihydronaphthalene-2-carbaldehyde
- the crystallization yield was evaluated by varying the dropwise addition rate, the dropwise temperature, or the order of addition of 3N HCl, and the results are shown in Table 3 below.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Crystallography & Structural Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
구분 | 염기 (equiv.) |
용매 | 온도 (℃) |
HPLC PAR (%) | 비고 | |
SG28 | SG35 | |||||
1 | K2CO3 (3) | Toluene | 23 | 40.0 | 60.0 | - |
2 | K2CO3 (3) | Toluene | 100 | 7.5 | 92.5 | - |
3 | K2CO3 (1) | MeOH | 23 | N/D | 100.0 | Initial SG28 7.5 % |
4 | 1N NaOH (1) | MeOH | 23 | N/D | 100.0 | Initial SG28 7.5 % |
5 | NaHCO3 (1) | MeOH | 23 | N/D | 100.0 | Initial SG28 7.5 % |
6 | K2CO3 (1) | EtOAc | 23 | N/D | 100.0 | Initial SG28 7.5 % |
7 | NaHCO3 (2) | MeOH | 50 | N/D | > 99 | 1 h에 반응 종결 |
8 | K2CO3 (2) | MeOH | 50 | N/D | > 99 | 1 h에 반응 종결 |
9 | NaOAc (2) | MeOH | 50 | N/D | 98.1 | 7.5 h에 반응 종결 |
10 | K2CO3 (2) | EtOAc | 50 | N/D | 35.1 | 7.5 h 에도 반응 종결 안됨 |
11 | 1N NaOH (2) | EtOAc | 50 | N/D | 2.2 | 7.5 h 에도 conversion 거의 없음 |
구분 | MeOH 증류 |
Condition (fold) | Net. Yield (%) |
1 | O | H2O (5) + 3N HCl (3 equiv.) → EtOAc (1) / n-Hex (3) | 75.0 |
2 | O | H2O (5) + 3N HCl (3 equiv.) → MTBE (3) / n-Hex (3) | 32.1(gross) |
3 | O | H2O (5) + 3N HCl (3 equiv.) → n-Hex (6) | 74.6 |
4 | X | H2O (5) + 3N HCl (3 equiv.) → n-Hex (10) | 86.6 |
5 | X | H2O (5) + 3N HCl (2 equiv.) | 83.0 |
6 | X | H2O (10) + 3N HCl (2 equiv.) | 78.2 |
7 | X | H2O (5) + 3N HCl (3 equiv.) | 83.9 |
구분 | 결정화 순서 |
적가 온도 (℃) |
3N HCl 적가 시간 |
응집 | 코팅 | 비고 | |
기벽 | 교반기 | ||||||
1 | 3N HCl → H2O | < 10 | 2 h | 상 | 상 | 상 | 1 L 반응기 test 반응 |
2 | 3N HCl → H2O | < 10 | 10 min | 중 | 하 | 하 | 검은 입자 코팅 후 갈색 입자로 전환 |
3 | 3N HCl → H2O | < 10 | 2 h | 상 | 상 | 중 | 검은 입자 코팅 후 갈색 입자로 전환 |
4 | H2O→3N HCl | < 10 | 10 min | 하 | 하 | 하 | 기벽 코팅 현상 없음, H2O 적가 시 약한 aggregation |
5 | 3N HCl → H2O | 30 ~ 35 | 10 min | 상 | 상 | 중 | 기벽 코팅 심함 |
6 | H2O→3N HCl | < 10 | 10 min | 하 | 하 | 하 | Entry 4 scale up test기벽과 교반기에 매우 약한 코팅 관찰, 그외 문제 없음 |
7 | 3N HCl → H2O | < 10 | 10 min | 상 | 상 | 상 | 기벽 상, 하부에 흑색 코팅,기벽 중간은 갈색 코팅 발생결정화 잘 되지 않고 검은 oil 형태의 SG35 얻음 |
구분 | Condition (fold) | N2 isomer (%) |
비고 |
1 | H2O (14) add stirring→ Dark solution, stick oil | - | 타르 과량 관찰됨Stick oil로 결정화 불가 |
2 | H2O (10) add MTBE (5) add, cooling, stirring | - | 결정화 안됨 |
3 | H2O (10) add MTBE (5) + HEX (5) add, cooling, stirring | - | 결정화 안됨 |
4 | EA extraction, NaOH (aq) washing DCM (3), MTBE (3), HEX (3) add | - | 결정화 안됨 |
5 | EA extraction, NaOH (aq) washing EtOH (4), HEX (4) add | 3.6 | 결정생성 양호 |
5-1 | Entry 5 MTBE (3) 세척 | 3.4 | - |
6 | EA extraction, NaOH (aq) washing EtOH (5), HEX (4) add | 3.0 | - |
7 | H2O (10) → EA (2), DCM (1) → clear →교반 중 소량의 입자 생성 → Hex (15) | 0.8 | 62.3 % 수율 |
8 | H2O (10) → EA (5) → clear →교반 중 입자 다량 생성 → H2O (10) | 1.0 | 57.8 % 수율 |
구분 | Condition (fold) | Purity (%) |
N2 isomer (%) |
Net. Yield (%) |
1 | H2O (10) / EtOH (2) mixture drop-wise | 88.9 | 3.0 | 87.4 |
2 | H2O (10) / EtOH (1) mixture drop-wise | 89.5 | 2.9 | 91.2 |
3 | H2O (10) / EtOH (4) mixture drop-wise | 91.0 | 2.8 | 93.4 |
4 | MTBE (2) → H2O (10) / EtOH (2) mixture drop-wise | 91.4 | 2.2 | 90.7 |
5 | Hex (2) →H2O (10) / EtOH (2) mixture drop-wise | 89.9 | 2.7 | 94.1 |
6 | H2O (10) / EtOH (3) / EA (1) | 91.1 | 2.8 | 94.4 |
7 | H2O (10) / EtOH (3) / DCM (1) | 90.4 | 2.7 | 94.6 |
8 | H2O (10) / EtOH (3) / THF (1) | 89.7 | 2.9 | 85.7 |
9 | H2O (10) / EtOH (3) / AN (1) | 90.0 | 2.9 | 93.2 |
10 | H2O (10) / MeOH (4) | 89.9 | 2.9 | 94.7 |
11 | H2O (10) / IPA (4) | 88.4 | 3.3 | 92.5 |
12 | H2O (10) / EtOH (4) at 30 ℃ | 90.4 | 2.8 | 82.9 |
13 | H2O (10) / EtOH (4) for 2h | 91.2 | 2.7 | 90.1 |
14 | H2O (10) / EtOH (4) poured | 90.1 | 2.8 | 93.8 |
15 | EtOH (4) → H2O (10) for 2h | 91.1 | 2.6 | 90.8 |
16 | MTBE (2) → H2O (10) / EtOH (4) for 2h | 95.6 | 1.4 | 82.5 |
17 | EA (2) → H2O (10) / EtOH (4) for 2h | 91.7 | 2.7 | 92.9 |
18 | MTBE (2) / EtOH (2) for 1h → H2O (10) for 1h | 92.3 | 2.2 | 91.9 |
19 | EA (2) / EtOH (2) for 1h → H2O (10) for 1h | 90.4 | 3.0 | 91.8 |
Claims (9)
- 화학식 2의 화합물과 화학식 3의 화합물을 커플링(coupling) 반응에 의해 화학식 4의 중간체 화합물을 제조하는 단계를 포함하는 화학식 4의 중간체 화합물의 제조 방법:[화학식 2][화학식 3][화학식 4]상기 화학식 2 내지 화학식 4에서,R1은 수소, 또는 치환 또는 비치환 알킬이고,R2는 수소, 치환 또는 비치환 알킬, 할로겐, CN, CF3 또는 COCF3이고,R3 및 R4는 각각 수소, 치환 또는 비치환 알킬, 또는 할로겐이고,R5는 수소, 치환 또는 비치환 알킬 또는 할로겐이고,X는 C 또는 N이고,L은 이탈기(leaving group)이다.
- 청구항 1에 있어서,R1은 C1-C4의 치환 또는 비치환된 알킬이고,R2는 할로겐이고,R3 및 R4는 각각 수소 또는 C1-C4의 치환 또는 비치환 알킬이고,R5는 할로겐이고,X는 N이고,L은 염소(Cl), 브로민(Br), 아이오딘(I), 메탄설포네이트(Oms), p-톨루엔설포네이트(OTs) 및 트리플루오로메탄설포네이트(OTf)로부터 선택되는 이탈기인 것인 제조방법.
- 청구항 1에 있어서,상기 화학식 4의 화합물을 결정화하는 단계를 포함하여 수득하는 것이며,상기 결정화를 위한 용매는 알코올계 용매를 포함하는 것인 제조방법.
- 청구항 3에 있어서,상기 결정화를 위한 용매는 알코올계 용매 및 물의 혼합 용매인 것인 제조방법.
- 청구항 5 또는 청구항 6에 있어서,상기 화학식 3의 화합물을 산성 조건에서 결정화하는 단계를 포함하여 수득하는 것인 제조방법.
- 청구항 7에 있어서,상기 결정화 단계는 상기 화학식 3의 화합물 함유 반응 생성물에 물을 투입한 후 염산을 투입하여 수행하는 것인 제조방법.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP22788465.7A EP4306513A1 (en) | 2021-04-14 | 2022-04-14 | Method for preparing intermediate for synthesis of sphingosine-1-phosphate receptor agonist |
CN202280028381.7A CN117242057A (zh) | 2021-04-14 | 2022-04-14 | 制备用于合成鞘氨醇-1-磷酸酯受体激动剂的中间体的方法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20210048765 | 2021-04-14 | ||
KR10-2021-0048765 | 2021-04-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022220610A1 true WO2022220610A1 (ko) | 2022-10-20 |
Family
ID=83640846
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2022/005398 WO2022220610A1 (ko) | 2021-04-14 | 2022-04-14 | 스핑고신-1-인산 수용체 효능제 합성을 위한 중간체의 제조방법 |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP4306513A1 (ko) |
KR (1) | KR102658762B1 (ko) |
CN (1) | CN117242057A (ko) |
TW (1) | TW202302538A (ko) |
WO (1) | WO2022220610A1 (ko) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102647663B1 (ko) * | 2020-10-13 | 2024-03-14 | 주식회사 엘지화학 | 스핑고신-1-인산 수용체 효능제 합성을 위한 중간체의 제조 방법 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1826197A1 (en) * | 2004-12-13 | 2007-08-29 | Ono Pharmaceutical Co., Ltd. | Aminocarboxylic acid derivative and medicinal use thereof |
US20110152241A1 (en) * | 2009-11-24 | 2011-06-23 | Allergan, Inc. | Novel compounds as receptor modulators with therapeutic utility |
KR20110140139A (ko) * | 2003-08-29 | 2011-12-30 | 오노 야꾸힝 고교 가부시키가이샤 | S1p 수용체 결합능을 갖는 화합물 및 그 의약 용도 |
KR20140104376A (ko) | 2013-02-20 | 2014-08-28 | 주식회사 엘지생명과학 | 스핑고신-1-인산 수용체 효능제, 그의 제조방법 및 그를 활성성분으로서 함유하는 약제학적 조성물 |
KR101589332B1 (ko) * | 2008-12-05 | 2016-01-27 | 아스텔라스세이야쿠 가부시키가이샤 | 2h-크로멘 화합물 및 그의 유도체 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6477A (en) * | 1987-03-24 | 1989-01-05 | Takeda Chem Ind Ltd | 1,4-disubstituted piperazine compound |
WO1997032837A1 (fr) | 1996-03-06 | 1997-09-12 | Sumitomo Pharmaceuticals Co., Ltd. | Derives estrogenes non steroidiens |
WO1999011255A1 (fr) | 1997-08-28 | 1999-03-11 | Ono Pharmaceutical Co., Ltd. | Regulateurs du recepteur active par les agents de proliferation des peroxysomes |
-
2022
- 2022-04-14 WO PCT/KR2022/005398 patent/WO2022220610A1/ko active Application Filing
- 2022-04-14 CN CN202280028381.7A patent/CN117242057A/zh active Pending
- 2022-04-14 TW TW111114182A patent/TW202302538A/zh unknown
- 2022-04-14 KR KR1020220046042A patent/KR102658762B1/ko active IP Right Grant
- 2022-04-14 EP EP22788465.7A patent/EP4306513A1/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20110140139A (ko) * | 2003-08-29 | 2011-12-30 | 오노 야꾸힝 고교 가부시키가이샤 | S1p 수용체 결합능을 갖는 화합물 및 그 의약 용도 |
EP1826197A1 (en) * | 2004-12-13 | 2007-08-29 | Ono Pharmaceutical Co., Ltd. | Aminocarboxylic acid derivative and medicinal use thereof |
KR101589332B1 (ko) * | 2008-12-05 | 2016-01-27 | 아스텔라스세이야쿠 가부시키가이샤 | 2h-크로멘 화합물 및 그의 유도체 |
US20110152241A1 (en) * | 2009-11-24 | 2011-06-23 | Allergan, Inc. | Novel compounds as receptor modulators with therapeutic utility |
KR20140104376A (ko) | 2013-02-20 | 2014-08-28 | 주식회사 엘지생명과학 | 스핑고신-1-인산 수용체 효능제, 그의 제조방법 및 그를 활성성분으로서 함유하는 약제학적 조성물 |
Also Published As
Publication number | Publication date |
---|---|
CN117242057A (zh) | 2023-12-15 |
KR20220142387A (ko) | 2022-10-21 |
KR102658762B1 (ko) | 2024-04-19 |
EP4306513A1 (en) | 2024-01-17 |
TW202302538A (zh) | 2023-01-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2020145627A1 (ko) | 글루포시네이트 제조 방법 | |
WO2020145513A1 (ko) | L-글루포시네이트 중간체 및 l-글루포시네이트 제조 방법 | |
WO2020067800A1 (ko) | 유기 발광 소자용 잉크 조성물 | |
WO2016129876A1 (ko) | 가소제 조성물, 수지 조성물 및 이들의 제조 방법 | |
WO2022220610A1 (ko) | 스핑고신-1-인산 수용체 효능제 합성을 위한 중간체의 제조방법 | |
WO2011154860A1 (en) | An improved process for preparing iloperidone | |
WO2022220612A1 (ko) | 스핑고신-1-인산 수용체 효능제 합성을 위한 중간체의 제조방법 | |
WO2021118003A1 (ko) | 신규 혈관누출 차단제의 고수율 제조방법 | |
EP2560955A2 (en) | Novel benzamide derivatives | |
WO2019066467A1 (ko) | (2r)-2-(2-메톡시페닐)-2-(옥산-4-일옥시)에탄-1-올 화합물의 신규 제조방법 및 이에 사용되는 중간체 | |
WO2015030440A1 (ko) | 히드록시아렌 붕소산 화합물의 열적 탈붕소수소화 및 이를 이용하여 페놀계 화합물의 오르소 또는 메타 위치에 작용기를 도입시킨 히드록시아렌 화합물의 제조방법 | |
WO2012044043A2 (en) | Novel method of preparing benzoimidazole derivatives | |
WO2011019179A2 (ko) | 청색 발광 이리듐 착물, 이리듐 착물 단량체, 인광 고분자 및 이를 이용한 유기전계발광소자 | |
WO2016108623A1 (en) | Novel method for preparing thienopyrimidine compound and intermediates used therein | |
WO2020036382A1 (ko) | Sglt 저해제의 합성에 유용한 중간체의 제조 | |
WO2022220613A1 (ko) | 스핑고신-1-인산 수용체 효능제의 신규한 제조방법 | |
WO2022220608A1 (ko) | 스핑고신-1-인산 수용체 효능제 합성을 위한 중간체의 제조방법 | |
WO2021194244A1 (ko) | 신규한 이노토디올의 제조방법 | |
WO2019107943A1 (ko) | Jak 저해제 화합물, 및 이의 제조방법 | |
WO2021225233A1 (ko) | 혈관 누출 차단제 화합물의 신규 결정형 | |
WO2022220611A1 (ko) | 스핑고신-1-인산 수용체 효능제의 신규한 제조방법 | |
WO2012157900A2 (ko) | 18f-표지 pet 방사성의약품의 전구체 및 그 제조방법 | |
WO2020045904A1 (ko) | 유기 발광 소자용 잉크 조성물 | |
WO2012033374A2 (ko) | 1,2,3-트리아졸륨 염을 갖는 설포네이트 전구체, 그 제조방법 및 이를 사용하는 분자내 친핵성 플루오르화반응 | |
WO2018124644A1 (ko) | 싸이에노피리미딘 화합물의 신규 제조방법 및 중간체 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22788465 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022788465 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 18555021 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202280028381.7 Country of ref document: CN |
|
ENP | Entry into the national phase |
Ref document number: 2022788465 Country of ref document: EP Effective date: 20231011 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |